OncoMatch/Clinical Trials/NCT06881784
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Is NCT06881784 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including daraxonrasib and docetaxel for nsclc (non-small cell lung cancer).
Treatment: daraxonrasib · docetaxel — The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS nonsynonymous mutation at codon 12, 13, or 61
Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Required: NRAS nonsynonymous mutation at codon 12, 13, or 61
Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Required: HRAS nonsynonymous mutation at codon 12, 13, or 61
Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
including an anti-PD-1/anti-PD(L)-1 agent
Must have received: platinum-based chemotherapy
including ... platinum-based chemotherapy
Cannot have received: RAS inhibitor
Prior therapy with direct RAS-targeted therapy
Cannot have received: taxane (docetaxel)
Prior therapy with ... docetaxel
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alabama Oncology · Birmingham, Alabama
- MemorialCare Long Beach Medical Center · Long Beach, California
- Yale University, Smillow Cancer Center · New Haven, Connecticut
- Florida Cancer Specialists & Research Institute - South · Fort Myers, Florida
- BRCR Global · Plantation, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06881784 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior RAS inhibitor, taxane disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS nonsynonymous mutation at codon 12, 13, or 61 is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS nonsynonymous mutation at codon 12, 13, or 61 is a required biomarker for enrollment.
Does this trial require HRAS?
Yes, HRAS nonsynonymous mutation at codon 12, 13, or 61 is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages